| Autor: |
Yonghao Xu, Ying Liu, Ruiqiang Zheng, Shujie Si, Yin Xi, Xilong Deng, Gang Wang, Liang Zhou, Manshu Li, Ya Wang, Shuo Zhang, Jianfeng Xie, Xiaoqing Liu, Yi Yang, Xiaoping Tang |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Intensive Care Research, Vol 3, Iss 2, Pp 103-111 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2666-9862 |
| DOI: |
10.1007/s44231-023-00040-9 |
| Popis: |
Abstract Objective Early intervention with neutralizing antibodies is considered to be effective in preventing disease progression in patients with mild to moderate COVID-19 infection. Elderly patients are the most susceptible and at a higher risk of COVID-19 infection. The present study aimed to assess the necessity and possible clinical benefits of the early administration of Amubarvimab/Romlusevimab (BRII-196/198) in the elderly population. Methods The present study was designed as a retrospective, multi-center cohort study conducted with 90 COVID-19 patients aged over 60, who were divided into two groups based on the timing of the administration of BRII-196/198 (administration at ≤ 3 days or > 3 days from the onset of infection symptoms). Results The ≤ 3 days group exhibited a greater positive effect (HR 5.94, 95% CI, 1.42–24.83; P 3 days group who exhibited disease progression. The multivariate Cox regression analysis revealed low flow oxygen support prior to BRII-196/198 administration (HR 3.53, 95% CI 1.42–8.77, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink